Neoadjuvant endocrine therapy often leads to breast and axilla‐conserving surgery in stages II and III hormone receptor‐positive breast cancer patients: A registry study
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70219 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Layla Andour und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoadjuvant Therapy, Mastectomy, Segmental, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bollenstreekfonds, Lisse.
Themen: Onkologische Pflege
Abstract (Originalsprache)
In stages II and III hormone receptor positive (HR+) breast cancer, selecting patients for primary surgery (PS) or neoadjuvant therapy remains challenging. This study assessed the occurrence of minimally invasive surgery in the case of PS, neoadjuvant endocrine therapy (NET), and neoadjuvant chemotherapy (NACT). This cohort study included women diagnosed with stages II and III, HR+ breast cancer in 2020–2022 in the Netherlands. Women with positive human epidermal growth factor receptor 2 (HER2+) cancer were excluded. Outcomes focused on surgical techniques and additional treatment. Of the 7809 patients, 4046 (51.8%) underwent PS, 956 (12.2%) received NET and 2807 (35.9%) NACT. NET patients were older (median: 71 years [33–94]), while NACT patients had larger tumors and more lymph node involvement ( p < .001). Breast‐conserving surgery (BCS) was the first procedure in 2153 (53.2%) PS women, in 694 (72.6%) NET women and 1564 (55.7%) NACT cases. There was no difference regarding free surgical margins in NET versus NACT patients ( p = .421). After adjusting for T‐stage, BCS occurred significantly more frequently after NET ( p < .001). Minimal invasive surgery on the axilla was common after NET (83.9%) and NACT (81.5%). In the PS group, 85% received adjuvant systemic therapy. Optimizing patient selection for neoadjuvant strategies could reduce surgical morbidity. NET was frequently associated with BCS, showed comparable surgical margin outcomes to NACT, and contributed to reduced axillary surgery. These findings suggest that NET is an effective strategy, compared to PS, to facilitate less invasive surgery on the breast and axilla, in HR+/HER2−, stages II and III breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Medical Statistics, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Surgery, Medical Center Haaglanden, The Hague, The Netherlands.
ORCID-Profile: Layla Andour
Förderung
- Bollenstreekfonds, Lisse
Zitieren
APA
Andour, L., Kroep, J. R., Putter, H., Tollenaar, R. A. E. M., Mesker, W. E., & Straver, M. E. (2026). Neoadjuvant endocrine therapy often leads to breast and axilla‐conserving surgery in stages II and III hormone receptor‐positive breast cancer patients: A registry study. International Journal of Cancer. https://doi.org/10.1002/ijc.70219
Vancouver
Andour L, Kroep JR, Putter H, Tollenaar RAEM, Mesker WE, Straver ME. Neoadjuvant endocrine therapy often leads to breast and axilla‐conserving surgery in stages II and III hormone receptor‐positive breast cancer patients: A registry study. International Journal of Cancer. 2026. doi:10.1002/ijc.70219
BibTeX
@article{Andour2026,
author = {Andour, Layla and Kroep, Judith R and Putter, Hein and Tollenaar, Rob A E M and Mesker, Wilma E and Straver, Marieke E},
title = {Neoadjuvant endocrine therapy often leads to breast and axilla‐conserving surgery in stages II and III hormone receptor‐positive breast cancer patients: A registry study},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70219}
}
EUVIMED